Wang Shaoping, Ran Yuhua, Chen Xuejun, Li Chungang, Cheng Shujuan, Liu Jinghua
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
Department of New Drug Evaluation, State Key Laboratory of Toxicology Medical Courtermeasures, Institute of Pharmacology and Toxicology, Beijing, China.
Front Pharmacol. 2020 Feb 21;11:101. doi: 10.3389/fphar.2020.00101. eCollection 2020.
The underlying mechanism of pleiotropic effects of statins on atherosclerosis is still unclear. Kv1.3 and KCa3.1 are two potassium channels that might be involved in monocyte migration and atherosclerosis formation. The aim of this study was to investigate the effect of simvastatin on the Kv1.3 and KCa3.1 in monocyte.
In human monocytic THP-1 cells, simvastatin significantly inhibited Kv1.3 mRNA and protein expression by real-time quantitative PCR analysis and western blotting. However, simvastatin had no effects on KCa3.1 mRNA and protein expression. By whole-cell patch clamp, simvastatin (10 μM) remarkably inhibited the current intensity of Kv1.3, but had no effect on KCa3.1. Simvastatin (10 μM) treatment significantly reduced the monocyte chemoattractant protein 1 (MCP-1)-induced monocyte migration. This inhibition was only partially reversed by mevalonate (1mM). In human peripheral blood mononuclear cells (PBMCs), both Kv1.3 and KCa3.1 mRNA expression were increased in patients with coronary artery diseases (CAD) (n = 20) compared to healthy controls (n = 22). However, simvastatin (40 mg per day) significantly inhibited the Kv1.3 but not KCa3.1 mRNA expression after 1 month and 3 months therapy in CAD patients.
Our data suggested Kv1.3 in monocytes was a potential molecular target of the pleiotropic effects of statins. KCa3.1 might be another marker of CAD, but not associated with statins treatment.
他汀类药物对动脉粥样硬化多效性作用的潜在机制仍不清楚。Kv1.3和KCa3.1是两个可能参与单核细胞迁移和动脉粥样硬化形成的钾通道。本研究旨在探讨辛伐他汀对单核细胞中Kv1.3和KCa3.1的影响。
在人单核细胞THP-1细胞中,通过实时定量PCR分析和蛋白质印迹法,辛伐他汀显著抑制Kv1.3 mRNA和蛋白质表达。然而,辛伐他汀对KCa3.1 mRNA和蛋白质表达无影响。通过全细胞膜片钳技术,辛伐他汀(10 μM)显著抑制Kv1.3的电流强度,但对KCa3.1无影响。辛伐他汀(10 μM)处理显著降低单核细胞趋化蛋白1(MCP-1)诱导的单核细胞迁移。甲羟戊酸(1mM)仅部分逆转了这种抑制作用。在人外周血单个核细胞(PBMCs)中,与健康对照者(n = 22)相比,冠心病(CAD)患者(n = 20)的Kv1.3和KCa3.1 mRNA表达均增加。然而,在CAD患者中,辛伐他汀(每天40 mg)治疗1个月和3个月后显著抑制Kv1.3 mRNA表达,但对KCa3.1无影响。
我们的数据表明,单核细胞中的Kv1.3是他汀类药物多效性作用的潜在分子靶点。KCa3.1可能是CAD的另一个标志物,但与他汀类药物治疗无关。